Academic Clinical Assistant, Hematology
Radboudumc, HTC-NEM
Nijmegen, Netherlands
Waander van Heerde studied chemistry at the University of Utrecht and graduated in 1990. He obtained his PhD at the Department of Biochemistry at the University of Utrecht in 1994. He then became a Postdoctoral Fellow at INSERM unité 143, Kremlin-Bicêtre, France, financed by INSERM, a talent stipend from the Netherlands Organization for Scientific Research (NWO), and the Foundation Recherche Médicale. In 1996 he was awarded a postdoctoral E. Dekker fellowship grant by the Netherlands Heart Foundation (research period 1997–2000) and moved to Maastricht University. In 2000 Dr van Heerde became director of the Thrombosis Hemostasis Research Department at the Radboudumc in Nijmegen, The Netherlands. From 2009–2013 he was founder and CEO/CSO of HaemoMagum BV a spin-off company of the Radboud Medical Centre (Radboudumc). In parallel with HaemoMagum, the Radboudumc founded a clinical research organization for laboratory diagnostics in thrombosis haemostasis (CRO-Nijmegen), which was managed by Dr van Heerde.
Since 2012, Dr van Heerde’s activities have been focused on personalized medicine, more particularly personalized diagnostics. In 2016 Dr van Heerde founded Enzyre BV (www.enzyre.com), a growing Radboudumc company and combined his activities at Enzyre with an appointment as a member of the management team of the Radboudumc Hemophilia Treatment Center (HTC), which merged with the HTCs of Eindhoven and Maastricht, Enzyre BV aims to develop a near patient disposable diagnostic platform to measure multiple enzymatic activities in small volumes of blood for patients that suffer from bleeding disorders. Dr vsan Heerde was member of the board of the Netherlands Society for Thrombosis and Haemostasis (NVTH), editor of the NVTH bulletin (2002–2008) and member of the Scientific Advisory Board of the Dutch Thrombosis Foundation from 2008–2017. Dr van Heerde has published over 100 peer-reviewed papers, has been a co-promotor of four PhD theses and inventor of eight patent applications (H-factor 35).